Entering text into the input field will update the search result below

Outlook Therapeutics files for FDA approval of ONS-5010 for eye disorder

Mar. 31, 2022 9:14 AM ETOutlook Therapeutics, Inc. (OTLK) StockBy: Ravikash Bakolia, SA News Editor6 Comments

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • Outlook Therapeutics (NASDAQ:OTLK) submitted an application to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet age-related macular degeneration (wet AMD).
  • The company said ONS-5010, if approved, will be branded as LYTENAVA (bevacizumab-vikg) for wet AMD, a chronic

Recommended For You

About OTLK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
OTLK--
Outlook Therapeutics, Inc.